Valley Forge Scientific
This article was originally published in The Gray Sheet
Repurchase of 10,200 shares brings to 15,200 the total number to date under a 200,000-share repurchase program. Valley Forge has about 8.2 mil. shares outstanding, approximately 5 mil. of which are publicly traded
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.